{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:57:39Z","timestamp":1790643459591,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05024-2","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:29:26Z","timestamp":1783333766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Hannah","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Filipic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Sarris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"5024_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/02791072.2021.1916659","volume":"54","author":"CE Mayer","year":"2022","unstructured":"Mayer CE, LeBaron VT, Acquaviva KD. Exploring the use of psilocybin therapy for existential distress: a qualitative study of palliative care provider perceptions. J Psychoact Drugs. 2022;54(1):81\u201392. https:\/\/doi.org\/10.1080\/02791072.2021.1916659.","journal-title":"J Psychoact Drugs"},{"key":"5024_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.genhosppsych.2025.02.023","volume":"94","author":"R Philipp","year":"2025","unstructured":"Philipp R, Walbaum C, Koch U, Oechsle K, Daniels T, Helmich F, et al. Existential distress in advanced cancer: a cohort study. Gen Hosp Psychiatry. 2025;94:184\u201391. https:\/\/doi.org\/10.1016\/j.genhosppsych.2025.02.023.","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"5024_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/medicina57090924","volume":"57","author":"PTP Wong","year":"2021","unstructured":"Wong PTP, Yu TTF. Existential suffering in palliative care: an existential positive psychology perspective. Med (Kaunas). 2021;57(9):924. https:\/\/doi.org\/10.3390\/medicina57090924.","journal-title":"Med (Kaunas)"},{"issue":"1","key":"5024_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/SPC.0000000000000324","volume":"12","author":"S Vehling","year":"2018","unstructured":"Vehling S, Philipp R. Existential distress and meaning-focused interventions in cancer survivorship. Curr Opin Support Palliat Care. 2018;12(1):46\u201351. https:\/\/doi.org\/10.1097\/SPC.0000000000000324.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"3","key":"5024_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/08980101211039086","volume":"40","author":"RH Lehto","year":"2022","unstructured":"Lehto RH, Miller M, Sender J. The role of psilocybin-assisted psychotherapy to support patients with cancer: a critical scoping review of the research. J Holist Nurs. 2022;40(3):265\u201380. https:\/\/doi.org\/10.1177\/08980101211039086.","journal-title":"J Holist Nurs"},{"issue":"3","key":"5024_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cpr.2007.07.013","volume":"28","author":"K LeMay","year":"2008","unstructured":"LeMay K, Wilson KG. Treatment of existential distress in life threatening illness: a review of manualized interventions. Clin Psychol Rev. 2008;28(3):472\u201393. https:\/\/doi.org\/10.1016\/j.cpr.2007.07.013.","journal-title":"Clin Psychol Rev"},{"issue":"15","key":"5024_CR7","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/cncr.31539","volume":"124","author":"W Breitbart","year":"2018","unstructured":"Breitbart W, Pessin H, Rosenfeld B, Applebaum AJ, Lichtenthal WG, Li Y, et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: a randomized controlled trial in patients with advanced cancer. Cancer. 2018;124(15):3231\u20139. https:\/\/doi.org\/10.1002\/cncr.31539.","journal-title":"Cancer"},{"issue":"4","key":"5024_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1017\/S147895151400073X","volume":"13","author":"P Gagnon","year":"2015","unstructured":"Gagnon P, Fillion L, Robitaille MA, Girard M, Tardif F, Cochrane JP, et al. A cognitive-existential intervention to improve existential and global quality of life in cancer patients: a pilot study. Palliat Support Care. 2015;13(4):981\u201390. https:\/\/doi.org\/10.1017\/S147895151400073X.","journal-title":"Palliat Support Care"},{"issue":"1","key":"5024_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12904-021-00889-x","volume":"20","author":"H Niles","year":"2021","unstructured":"Niles H, Fogg C, Kelmendi B, Lazenby M. Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliat Care. 2021;20(1):191. https:\/\/doi.org\/10.1186\/s12904-021-00889-x.","journal-title":"BMC Palliat Care"},{"key":"5024_CR10","doi-asserted-by":"publisher","first-page":"103728","DOI":"10.1016\/j.critrevonc.2022.103728","volume":"176","author":"NH Hart","year":"2022","unstructured":"Hart NH, Crawford-Williams F, Crichton M, Yee J, Smith TJ, Koczwara B, et al. Unmet supportive care needs of people with advanced cancer and their caregivers: a systematic scoping review. Crit Rev Oncol Hematol. 2022;176:103728. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103728.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"5024_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1177\/02698811221092508","volume":"36","author":"R Smausz","year":"2022","unstructured":"Smausz R, Neill J, Gigg J. Neural mechanisms underlying psilocybin\u2019s therapeutic potential \u2013 the need for preclinical in vivo electrophysiology. J Psychopharmacol. 2022;36(7):781\u201393. https:\/\/doi.org\/10.1177\/02698811221092508.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"5024_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). 2020;73(10):679\u201386. https:\/\/doi.org\/10.1038\/s41429-020-0311-8.","journal-title":"J Antibiot (Tokyo)"},{"key":"5024_CR13","unstructured":"Australian Government Department of Health and Aged Care \u2013 Therapeutic Goods Administration. Update on MDMA and psilocybin access and safeguards from 1 July 2023. Australian Government Department of Health and Aged Care. 2023. Available from: https:\/\/www.tga.gov.au\/news\/news-articles\/update-mdma-and-psilocybin-access-and-safeguards-1-july-2023 accessed 30 July 2025."},{"issue":"1","key":"5024_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1556\/2054.2019.015","volume":"4","author":"JR George","year":"2019","unstructured":"George JR, Michaels TI, Sevelius J, Williams MT. The psychedelic renaissance and the limitations of a White-dominant medical framework: a call for indigenous and ethnic minority inclusion. J Psychedelic Stud. 2019;4(1):4\u201315. https:\/\/doi.org\/10.1556\/2054.2019.015.","journal-title":"J Psychedelic Stud"},{"issue":"9","key":"5024_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.12345","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843\u201353. https:\/\/doi.org\/10.1001\/jama.2023.12345.","journal-title":"JAMA"},{"issue":"5","key":"5024_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481\u20139.","journal-title":"JAMA Psychiatry"},{"issue":"4\u20136","key":"5024_CR17","first-page":"39","volume":"20","author":"WW IsHak","year":"2023","unstructured":"IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, et al. The impact of psilocybin on patients experiencing psychiatric symptoms: a systematic review of randomized clinical trials. Innov Clin Neurosci. 2023;20(4\u20136):39.","journal-title":"Innov Clin Neurosci"},{"issue":"12","key":"5024_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11920-022-01394-5","volume":"24","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS. Psychedelic-assisted therapy for people with eating disorders. Curr Psychiatry Rep. 2022;24(12):767\u201375. https:\/\/doi.org\/10.1007\/s11920-022-01394-5.","journal-title":"Curr Psychiatry Rep"},{"key":"5024_CR19","doi-asserted-by":"publisher","first-page":"866018","DOI":"10.3389\/fpsyg.2022.866018","volume":"13","author":"W Brennan","year":"2022","unstructured":"Brennan W, Belser AB. Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a transdiagnostic, trans-drug model. Front Psychol. 2022;13:866018. https:\/\/doi.org\/10.3389\/fpsyg.2022.866018.","journal-title":"Front Psychol"},{"key":"5024_CR20","doi-asserted-by":"publisher","first-page":"1054692","DOI":"10.3389\/fpsyg.2023.1054692","volume":"14","author":"J Gre\u0144","year":"2023","unstructured":"Gre\u0144 J, Tyl\u0161 F, Lasocik M, Kiraly C. Back from the rabbit hole: theoretical considerations and practical guidelines on psychedelic integration for mental health specialists. Front Psychol. 2023;14:1054692. https:\/\/doi.org\/10.3389\/fpsyg.2023.1054692.","journal-title":"Front Psychol"},{"key":"5024_CR21","doi-asserted-by":"publisher","first-page":"824077","DOI":"10.3389\/fpsyg.2022.824077","volume":"13","author":"GJ Bathje","year":"2022","unstructured":"Bathje GJ, Majeski E, Kudowor M. Psychedelic integration: an analysis of the concept and its practice. Front Psychol. 2022;13:824077. https:\/\/doi.org\/10.3389\/fpsyg.2022.824077.","journal-title":"Front Psychol"},{"issue":"10","key":"5024_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.30773\/pi.2021.0209","volume":"18","author":"C-L Yu","year":"2021","unstructured":"Yu C-L, Yang F-C, Yang S-N, Tseng P-T, Stubbs B, Yeh T-C, et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. Psychiatry Investig. 2021;18(10):958\u201367. https:\/\/doi.org\/10.30773\/pi.2021.0209.","journal-title":"Psychiatry Investig"},{"issue":"12","key":"5024_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"5024_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155\u201366. https:\/\/doi.org\/10.1177\/0269881119897615.","journal-title":"J Psychopharmacol"},{"key":"5024_CR25","doi-asserted-by":"publisher","first-page":"114727","DOI":"10.1016\/j.psychres.2022.114727","volume":"316","author":"TD Meyer","year":"2022","unstructured":"Meyer TD, Meir P, Lex C, Soares JC. Magic mushrooms \u2013 an exploratory look at how mental health professionals feel and think about psilocybin. Psychiatry Res. 2022;316:114727. https:\/\/doi.org\/10.1016\/j.psychres.2022.114727.","journal-title":"Psychiatry Res"},{"issue":"4","key":"5024_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2021.1971343","volume":"54","author":"AK Davis","year":"2022","unstructured":"Davis AK, Agin-Liebes G, Espa\u00f1a M, Pilecki B, Luoma J. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J Psychoact Drugs. 2022;54(4):309\u201318. https:\/\/doi.org\/10.1080\/02791072.2021.1971343.","journal-title":"J Psychoact Drugs"},{"issue":"3","key":"5024_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/02791072.2021.195718","volume":"54","author":"BS Barnett","year":"2022","unstructured":"Barnett BS, Beaussant Y, King F, Doblin R. Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey. J Psychoactive Drugs. 2022;54(3):269\u2009\u2013\u200977. https:\/\/doi.org\/10.1080\/02791072.2021.195718","journal-title":"J Psychoactive Drugs"},{"issue":"11","key":"5024_CR28","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/eat.24041","volume":"56","author":"AE Downey","year":"2023","unstructured":"Downey AE, Boyd M, Chaphekar AV, Woolley J, Raymond-Flesch M. But the reality is it\u2019s happening: a qualitative study of eating disorder providers about psilocybin-assisted psychotherapy. Int J Eat Disord. 2023;56(11):2142\u20138. https:\/\/doi.org\/10.1002\/eat.24041.","journal-title":"Int J Eat Disord"},{"key":"5024_CR29","doi-asserted-by":"publisher","first-page":"743599","DOI":"10.3389\/fpsyt.2021.743599","volume":"12","author":"LA Page","year":"2021","unstructured":"Page LA, Rehman A, Syed H, Forcer K, Campbell G. The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Front Psychiatry. 2021;12:743599. https:\/\/doi.org\/10.3389\/fpsyt.2021.743599.","journal-title":"Front Psychiatry"},{"key":"5024_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jad.2022.12.050","volume":"323","author":"P Meir","year":"2023","unstructured":"Meir P, Taylor L, Soares JC, Meyer TD. Psychotherapists\u2019 openness to engage their patients in psilocybin-assisted therapy for mental health treatment. J Affect Disord. 2023;323:748\u201354. https:\/\/doi.org\/10.1016\/j.jad.2022.12.050.","journal-title":"J Affect Disord"},{"issue":"1","key":"5024_CR31","doi-asserted-by":"publisher","first-page":"28022","DOI":"10.1038\/s41598-024-78736-1","volume":"14","author":"E Wang","year":"2024","unstructured":"Wang E, Mathai DS, Gukasyan N, Nayak S, Garcia-Romeu A. Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among US healthcare professionals. Sci Rep. 2024;14(1):28022. https:\/\/doi.org\/10.1038\/s41598-024-78736-1.","journal-title":"Sci Rep"},{"issue":"4","key":"5024_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1017\/S1478951522001481","volume":"22","author":"LM Reynolds","year":"2024","unstructured":"Reynolds LM, Barnett B, Weleff J, Morunga E, Wells A, Stack A, et al. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: a cross-sectional survey. Palliat Support Care. 2024;22(4):664\u201373. https:\/\/doi.org\/10.1017\/S1478951522001481.","journal-title":"Palliat Support Care"},{"issue":"1","key":"5024_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dar.13973","volume":"44","author":"JJ Negrine","year":"2025","unstructured":"Negrine JJ, Puljevi\u0107 C, Ferris J, Liknaitzky P, Perlman C, Piatkowski T. Australian psychologists\u2019 attitudes towards psychedelic-assisted therapy and training following a world-first drug down-scheduling. Drug Alcohol Rev. 2025;44(1):336\u201346. https:\/\/doi.org\/10.1111\/dar.13973.","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"5024_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/papt.12545","volume":"97","author":"M Barber","year":"2024","unstructured":"Barber M, Gardner J, Liknaitzky P, Carter A. Lost in translation? Qualitative interviews with Australian psychedelic-assisted therapy trial clinicians. Psychol Psychother. 2024;97(4):626\u201344. https:\/\/doi.org\/10.1111\/papt.12545.","journal-title":"Psychol Psychother"},{"issue":"7","key":"5024_CR35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/cncr.35024","volume":"130","author":"Y Beaussant","year":"2024","unstructured":"Beaussant Y, et al. Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: qualitative analysis. Cancer. 2024;130(7):1147\u201357. https:\/\/doi.org\/10.1002\/cncr.35024.","journal-title":"Cancer"},{"key":"5024_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106070","author":"WR Smith","year":"2020","unstructured":"Smith WR, Sisti D. Ethics and ego dissolution: the case of psilocybin. J Med Ethics. 2020. https:\/\/doi.org\/10.1136\/medethics-2020-106070. medethics-2020-106070.","journal-title":"J Med Ethics"},{"issue":"10","key":"5024_CR37","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1177\/02692163251393561","volume":"39","author":"JJ Sanders","year":"2025","unstructured":"Sanders JJ, Beaussant Y. Feeling groovy? The present and future of psychedelic research in palliative care. Palliat Med. 2025;39(10):1034\u20136. https:\/\/doi.org\/10.1177\/02692163251393561.","journal-title":"Palliat Med"},{"issue":"2","key":"5024_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/2159676X.2019.1704846","volume":"13","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V. To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales. Qual Res Sport Exerc Health. 2019;13(2):201\u201316. https:\/\/doi.org\/10.1080\/2159676X.2019.1704846.","journal-title":"Qual Res Sport Exerc Health"},{"issue":"3","key":"5024_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/14780887.2020.1769238","volume":"18","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qual Res Psychol. 2021;18(3):328\u201352. https:\/\/doi.org\/10.1080\/14780887.2020.1769238.","journal-title":"Qual Res Psychol"},{"issue":"1","key":"5024_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/26895269.2022.2129597","volume":"24","author":"V Braun","year":"2022","unstructured":"Braun V, Clarke V. Toward good practice in thematic analysis: avoiding common problems and be(com)ing a knowing researcher. Int J Transgend Health. 2022;24(1):1\u20136. https:\/\/doi.org\/10.1080\/26895269.2022.2129597.","journal-title":"Int J Transgend Health"},{"key":"5024_CR41","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s11135-021-01182-y","volume":"56","author":"D Byrne","year":"2022","unstructured":"Byrne D. A worked example of Braun and Clarke\u2019s approach to reflexive thematic analysis. Qual Quant. 2022;56:1391\u2013412. https:\/\/doi.org\/10.1007\/s11135-021-01182-y.","journal-title":"Qual Quant"},{"key":"5024_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.36834\/cmej.72504","volume":"73","author":"N Cofie","year":"2022","unstructured":"Cofie N, Braund H, Dalgarno N. Eight ways to get a grip on intercoder reliability using qualitative-based measures. Can Med Educ J. 2022;73:6. https:\/\/doi.org\/10.36834\/cmej.72504.","journal-title":"Can Med Educ J"},{"issue":"1","key":"5024_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/hex.13642","volume":"26","author":"RE Olson","year":"2023","unstructured":"Olson RE, Smith A, Good P, Dudley M, Gurgenci T, Hardy J. What price do you put on your health?\u2019: medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer. Health Expect. 2023;26(1):160\u201371. https:\/\/doi.org\/10.1111\/hex.13642.","journal-title":"Health Expect"},{"issue":"1","key":"5024_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-10-2","volume":"10","author":"J Bottorff","year":"2013","unstructured":"Bottorff J, Bissell L, Balneaves L, Buxton J, Capler N, Oliffe J. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J. 2013;10(1):1\u201310. https:\/\/doi.org\/10.1186\/1477-7517-10-2.","journal-title":"Harm Reduct J"},{"issue":"3","key":"5024_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258\u201372. https:\/\/doi.org\/10.1177\/02698811211069100.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"5024_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","volume":"66","author":"BR Lewis","year":"2023","unstructured":"Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A, et al. HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with cancer. J Pain Symptom Manage. 2023;66(3):258\u201369. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.06.006.","journal-title":"J Pain Symptom Manage"},{"key":"5024_CR47","doi-asserted-by":"publisher","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","volume":"14","author":"E Marseille","year":"2023","unstructured":"Marseille E, Stauffer CS, Agrawal M. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Front Psychiatry. 2023;14:1293243. https:\/\/doi.org\/10.3389\/fpsyt.2023.1293243.","journal-title":"Front Psychiatry"},{"issue":"4","key":"5024_CR48","doi-asserted-by":"publisher","first-page":"e245960","DOI":"10.1001\/jamanetworkopen.2024.5960","volume":"7","author":"A Yerubandi","year":"2024","unstructured":"Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(4):e245960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5960.","journal-title":"JAMA Netw Open"},{"key":"5024_CR49","unstructured":"Hou YN. Gubili. Psilocybin. The Asco Post. 2023. https:\/\/ascopost.com\/issues\/october-10-2023\/psilocybin\/"},{"issue":"3","key":"5024_CR50","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, et al. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258\u201372. https:\/\/doi.org\/10.1177\/02698811211069100.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"5024_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12152-023-09536-z","volume":"17","author":"E Jacobs","year":"2024","unstructured":"Jacobs E, Murphy-Beiner A, Rouiller I, Nutt D, Spriggs MJ. When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. Neuroethics. 2024;17(1):3. https:\/\/doi.org\/10.1007\/s12152-023-09536-z.","journal-title":"Neuroethics"},{"key":"5024_CR52","doi-asserted-by":"publisher","first-page":"100410","DOI":"10.1016\/j.lana.2022.100410","volume":"18","author":"Y Celidwen","year":"2022","unstructured":"Celidwen Y, Redvers N, Githaiga C, Calamb\u00e1s J, A\u00f1a\u00f1os K, Chindoy ME, et al. Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice. Lancet Reg Health Am. 2022;18:100410. https:\/\/doi.org\/10.1016\/j.lana.2022.100410.","journal-title":"Lancet Reg Health Am"},{"issue":"1611","key":"5024_CR53","first-page":"79","volume":"138","author":"C Hanna","year":"2025","unstructured":"Hanna C, Morunga E, Wells A, Reynolds L. Maori healthcare professionals\u2019 perceptions of psychedelic-assisted therapy: a qualitative study. N Z Med J. 2025;138(1611):79\u201392.","journal-title":"N Z Med J"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05024-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:59:44Z","timestamp":1790639984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05024-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5024"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05024-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the St Vincent Hospital Human Resource Ethics Committee (HREC) (2023\/ETH00860), with site-specific approvals granted by Chris O\u2019Brien Lifehouse and Peter MacCallum Cancer Centre. All participants provided consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS1 is an Executive Director of Neurala Biosciences and the connected not-for-profit Psyche Institute, which are both involved with psychedelics research and the development of these agents as registered medicines. He is employed and holds equity with Neurala Biosciences. He is also an advisory board representative for HedoniaUSA, which formulates and sells nutraceutical products. He also has received either presentation honoraria, travel support, clinical trial grants, book royalties, or independent consultancy payments from: Integria Healthcare & MediHerb, Pfizer, Scius Health, Key Pharmaceuticals, Taki Mai, Fiji Kava, Noetic Foundry, FIT-BioCeuticals, Blackmores, Soho-Flordis, Healthworld, HealthEd, HealthMasters, Kantar Consulting, Angelini Pharmaceuticals, Grunbiotics, Polistudium, Global Pharma Group, Australian Natural Therapeutics Group, Research Reviews, Elsevier, Chaminade University, International Society for Affective Disorders, Complementary Medicines Australia, SPRIM, Terry White Chemists, ANS, Society for Medicinal Plant and Natural Product Research, Sanofi-Aventis, Omega-3 Centre, the National Health and Medical Research Council, CR Roper Fellowship, Medical Research Futures Fund, CSIRO Australia, Launch Victoria, Genesis Fund, Tin Alley Ventures. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"528"}}